1. Home
  2. AKRO vs LKFN Comparison

AKRO vs LKFN Comparison

Compare AKRO & LKFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • LKFN
  • Stock Information
  • Founded
  • AKRO 2017
  • LKFN 1872
  • Country
  • AKRO United States
  • LKFN United States
  • Employees
  • AKRO N/A
  • LKFN N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • LKFN Major Banks
  • Sector
  • AKRO Health Care
  • LKFN Finance
  • Exchange
  • AKRO Nasdaq
  • LKFN Nasdaq
  • Market Cap
  • AKRO 2.0B
  • LKFN 1.8B
  • IPO Year
  • AKRO 2019
  • LKFN 1997
  • Fundamental
  • Price
  • AKRO $25.14
  • LKFN $68.39
  • Analyst Decision
  • AKRO Strong Buy
  • LKFN Hold
  • Analyst Count
  • AKRO 8
  • LKFN 3
  • Target Price
  • AKRO $46.83
  • LKFN $71.00
  • AVG Volume (30 Days)
  • AKRO 842.7K
  • LKFN 135.1K
  • Earning Date
  • AKRO 02-27-2025
  • LKFN 01-24-2025
  • Dividend Yield
  • AKRO N/A
  • LKFN 2.81%
  • EPS Growth
  • AKRO N/A
  • LKFN 9.99
  • EPS
  • AKRO N/A
  • LKFN 3.85
  • Revenue
  • AKRO N/A
  • LKFN $242,401,000.00
  • Revenue This Year
  • AKRO N/A
  • LKFN N/A
  • Revenue Next Year
  • AKRO N/A
  • LKFN $2.24
  • P/E Ratio
  • AKRO N/A
  • LKFN $17.77
  • Revenue Growth
  • AKRO N/A
  • LKFN 3.62
  • 52 Week Low
  • AKRO $15.32
  • LKFN $57.45
  • 52 Week High
  • AKRO $37.00
  • LKFN $78.61
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.89
  • LKFN 45.99
  • Support Level
  • AKRO $21.34
  • LKFN $67.51
  • Resistance Level
  • AKRO $28.94
  • LKFN $71.09
  • Average True Range (ATR)
  • AKRO 1.38
  • LKFN 1.87
  • MACD
  • AKRO -0.27
  • LKFN 0.11
  • Stochastic Oscillator
  • AKRO 49.67
  • LKFN 55.59

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.

Share on Social Networks: